EASL2012:Downregulation of NK Cell Phenotype and Function in HBV Patients Treate

StephenW

Abstract               
                                

Title	Downregulation of NK Cell Phenotype and Function in HBV Patients Treated with Entecavir
Speaker:	Yanfang   Jiang
Author:	X. Sun, P. Zhao, J. Tai, J. Feng, J. Niu, Y. Jiang*
Affiliation:	First Hospital, Jilin University, Changchun, China. *[email protected]
Background: During the early phase ofhepatitis B virus (HBV) infection, the activation of NK cells seems to be animportant factor determining the subsequent induction of adaptive immunity and ultimatelythe outcome of HBV infection. This study aimed to investigate phenotype andfunction of NK cells in patients with chronic HBV infection and to study theeffect of entecavir therapy. Methods: Peripheral blood NK cells from 18chronic HBV patients were compared to NK cells of 14 healthy controls. Theeffect of entecavir therapy on the phenotype and function of NK cells inpatients with chronic HBV infection were characterized by flow cytometryanalysis. Their serum alanine aminotranferease (ALT) and aspartateaminotransferase (AST) concentrations, and HBV viral loads were measured. Thepotential association of the frequency of peripheral NK cells sbuset withclinical measures was analyzed. Results: Characterization of NK cells subsets revealed that CD3-CD56+ NKcells were significant reduced in HBV patients compared to healthy control. Nosignificant difference about the percentages of NK cells was found after entecavir treatment.Furthermore, we analyzed NK cell receptor expression in the two groups ofindividuals and included natural activation receptors and inhibitory receptors.Interestingly, We found the percentages of activation receptors CD3-CD56+NKG2D+and CD3-CD56+NKP30+ NK cells in HBVpatients which were significantly higher than healthy individuals were down-regulatedafter entecavir treatment. However, there was no significant changed about theexpression of inhibitory receptors was found after entecavir treatment. Spearman'scorrelation analysis revealed that the percentage of NKG2D+ and NKP30+ NK cells was significantly positivelycorrelated with the serumALT in HBV patients. Characterizationof NK cell degranulation indicated that the frequency of CD107a+ NK cells in patients with HBV,in response to K562 stimulation, which was significantly higher than that inhealthy controls was decreased in patients after entecavir treatment. Conclusions: These data examined thatafter entecavir treatment of HBeAb-positive chronic HBV patients in China not only leadsto the reduction of HBV DNA load and normalization of ALT and AST but also canrecovery the NK cell-mediated immunity in chronic HBV patients.

StephenW

标题与恩替卡韦治疗乙型肝炎患者的NK细胞表型和功能的下调
主讲人：张艳芳江
作者：十孙，P.赵，J.大，J.冯，J.牛，华江*
单位：第一医院，吉林大学，长春，中国。 * [email protected]
背景：在乙型肝炎病毒（HBV）感染的早期阶段，激活NK细胞似乎是一个重要的因素，确定随后的诱导适应性免疫和乙肝病毒感染的最终结果。本研究旨在探讨慢性乙肝病毒感染患者的NK细胞表型和功能的研究恩替卡韦治疗的效果。
方法：18例慢性乙型肝炎患者外周血NK细胞进行比较，以14名健康对照组的NK细胞。恩替卡韦治疗慢性乙型肝炎患者的NK细胞的表型和功能的影响进行了表征，通过流式细胞仪分析。其血清丙氨酸aminotranferease（ALT）和天冬氨酸转氨酶（AST）浓度，HBV病毒载量测定。潜在的关联进行了分析与临床措施sbuset外周血NK细胞的频率。
结果：NK细胞亚群的表征发现的CD3-CD56 + NK细胞在乙肝患者与健康对照组相比有显着性降低。发现恩替卡韦治疗后NK细胞的百分比无显着差异。此外，我们分析了个人两组NK细胞受体的表达，包括自然激活受体和抑制性受体。有趣的是，我们发现的百分比激活受体的CD3-CD56 + NKG2D的+和CD3-CD56 +细胞NKP30 + NK细胞在细胞均显着高于健康人高的乙肝患者，恩替卡韦治疗后下调。然而，有恩替卡韦治疗后发现没有改变显著的抑制性受体的表达。 Spearman相关分析显示，NKG2D的百分比+ NKP30 + NK细胞显着正与乙肝患者serumALT相关的。 NK细胞脱颗粒的表征表明，频率CD107a + NK细胞在乙肝患者，在K562细胞的刺激，这是显着高于健康对照下降后，恩替卡韦治疗的患者高出。
结论：这些数据的研究，恩替卡韦在中国的抗 -  HBe阳性的慢性乙肝患者的治疗后，不仅减少HBV DNA载量和ALT和AST正常化，但也可以恢复在慢性乙型肝炎患者的NK细胞介导的​​免疫力。